Akrivis Technologies, LLC is a privately held life sciences company founded in 2009 and committed to the development and commercialization of products and services for the early detection and treatment of serious human diseases.

Akrivis’ main asset is its proprietary Z–TECT^™ Technology Platform which provides ultrasensitive detection and accurate quantification of biomolecules present in the zeptomole range (10E–21 moles), therefore allowing the detection of less than a thousand individual molecules. In addition to supporting in vitro and in vivo diagnostics, Z–TECT^™ can also serve as a novel platform for the targeted delivery of radio– and chemo–therapeutic drugs for cancer treatments. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z–TECT^™ could have a major impact on the emerging field of “Theranostics” which combines cancer therapies with companion in vivo imaging diagnostics.